Encouraging results from our phase-I trial (NADPARK)

Encouraging results from our phase-I trial (NADPARK)! Oral nicotinamide riboside holds promise as a neuroprotective therapy for Parkinson’s disease.

[visual-link-preview encoded=”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”]